Objective: To evaluate our treatment of renal artery in-stent restenosis. Patients and methods: Monocentric retrospective study of 53 cases of restenosis and two occlusions in 51 patients detected via systematic follow-up with imaging (72.5%) and/or deterioration of kidney function (5.9%) and/or blood pressure failure (54.9%), 15.7 months (5-121) after implantation, giving rise to 49 recalibrations via a balloon and five additional stentings. Analysis of the technical results, the effects on blood pressure and kidney function after repeated revascularizations. Results: Secondary permeability of 38 arteries (63.2%) after 12.4 months (3-64) with 14 second restenoses; 33.3% after redilation with a balloon, 60% after renewed stenting, more common in smokers (P = 0.02), in case of peripheral arterial disease (P = 0.02), ostial location (P = 0.049) and kidney function impairment at the time of diagnosis of the restenosis (P = 0.012). After 12.7 months (3-64) post-revascularization, kidney function was improved in 30% of patients and stabilised in 50% of patients. Treatment of second restenoses: one failure (7.1%), nine dilations with a balloon, three cutting balloon, one second stent. Treatment of third restenoses: 71.4% treated with a balloon (2), cutting balloon (2) or coated stent (DES) (1); then permeability at a later point in time: 50%. Conclusion: The treatment of repeated restenoses with conventional techniques is of imperfect efficacy, and currently remains un-codified.
less convincing results regarding the real clinical benefit, without however avoiding methodological criticism [5] .
Restenosis after angioplasty is one of the major limits of these percutaneous revascularization techniques. Stenting has not resolved this problem. In the meta-analysis by Leertouwer et al. [6] , the restenosis rate was 26% after use of a simple balloon and 17% after stenting. In the ISLES metaanalysis, the restenosis rate after stenting was estimated to be 16%, generally occurring after 6 to 12 months [7] . There is no consensus on the measures to be taken with regard to these in-stent restenoses of the renal arteries (RAs).
In this article, we present the summary of our experience with this situation, by retrospectively studying a series of 51 consecutive patients treated in our centre.
Patients and methods
Fifty-one consecutive patients had percutaneous atheromatous renal artery in-stent restenosis (ARAIR) in our centre from November 2002 to March 2007.
These patients included 25 men and 26 women with a mean age of 68.4 years (45-83). Four patients were treated for bilateral ARAIR at the same time. Therefore, 55 procedures concerning 53 in-stent restenoses and two in-stent occlusions were studied. One male patient had both polar RA in-stent restenosis and homolateral principal ARAS, which benefited from primary stenting. Finally, one female patient had an occlusion of the RA that was contralateral to the ARAIR, which was not treated. The benefit/risk ratio was considered to be low.
There were 40 single RAs and 15 kidneys perfused by multiple RAs. In these cases, the restenosed stented RA was thus either a principal RA [13] or a polar RA [2] .
The initial RAS was in an ostial location in 87% of cases and non ostial in 13% (seven stents); the two occluded stents were in an ostial location. The model, diameter and length of the stents in question are presented in Table 1 .
In 37 patients, the ARAIR diagnosis was established via a systematic control of the permeability of the stent that was scheduled by our team, theoretically 6 months after implantation by Doppler sonography and/or angiography scan of the RAs after a mean of 7 months with extreme values of 5 and 11 months. The mean time between the initial stenting and the treatment of the ARAIR was 15.7 months with extreme values of 5 and 121 months. We could differentiate two groups among these 37 patients: for 17 of them, blood pressure control was not satisfactory despite the medical treatment; for two of them, there was isolated deterioration of kidney function, while for 18 patients, the blood pressure and kidney function status were considered acceptable.
For the other 14 patients, the diagnosis of ARAIR was made a long period of time after the initial stenting, i.e. after a mean of 39 months (maximum of 121, minimum of 11), though these patients had poor blood pressure control [11] , isolated deterioration of kidney function [1] , or the combination of blood pressure and kidney function disturbances in two of them.
Our criteria for in-stent restenosis were as follows: • on the Doppler sonography, a systolic velocity peak of more than 250 cm/s with an aortal-renal ratio of more than 4;
• on the angiography scan, a reduction in calibre of more than 50%.
All of these ARAIRs were confirmed by arteriography as per the usual criteria: a reduction in the diameter of the in-stent lumen of 50% or more [1, 8] .
All of these in-stent revascularizations were carried out using the coaxial angioplasty technique. We generally began with a dilation using a simple balloon, using a balloon with the same diameter or possibly a diameter that was one millimetre wider than that of the balloon used during the initial implantation of the stent. If necessary, we could complete the procedure with the implantation of a second bare stent, inside the first stent or right downstream from it. At the time of inclusion in this series, we only had coated stents within the framework of the GREAT protocol [9, 10] . The patient who had an implantation of the coated stent was included in this protocol. The nominal diameter of this stent (Palmaz Blue, Cordis, coated with Sirolimus) was the same as the diameter of the bare stent that was already in place. Finally, cutting balloons (Boston Scientific, Donegal, Republic of Ireland) were used. In this case, there was no pre-dilation using a simple balloon, and the diameter of the cutting balloon was 1 mm less than that of the stents that were initially implanted.
During the procedure, anti-coagulation (1000 to 3000 units) with Heparin was injected in situ. Afterwards, nonfractionated heparin was administered via a pump for 48 hours, while a simple platelet anti-aggregant was continued (acetylsalicylic acid, 125 mg per day, or Clopidogrel, 75 mg per day).
Technical success was defined angiographically as the absence of residual stenosis of more than 30%. The complications were defined by applying the Rundback criteria [1] . A systematic control was scheduled 6 months after in-stent revascularization for morphological (permeability of the stent), clinical (blood pressure, kidney function) and laboratory test evaluation.
The clinical results (blood pressure and kidney function) were analysed using the reference criteria [1, 8] .
The statistical analysis used the Chi 2 test for quantitative variables. When the theoretical number of patients was less than 5, a Fisher's exact test was used. For qualitative variables, we used the Student's t test.
Results
During the treatment of the first ARAIRs, there was one technical failure (1.8%) and there were two complications: two cases of acute oedema of the lungs (3.6%) after the procedure, the course of which was rapidly favourable under suitable medical treatment, with no impact on the permeability of the stent. There was no mortality within the first 30 days.
Forty-nine recalibrations with a simple balloon (89.1%) were carried out with success, including one occluded stent, which was re-canalised. The implantation of an additional stent was necessary five times (three stents mounted on a small balloon and two self-expandable stents).
In four cases, a stent was implanted within the stent, including in one case to ensure the re-canalisation of an occlusion. One stent was even implanted overlapping the extremity of the initial stent and the downstream artery for restenosis at the outlet of the stent. Of these 50 patients, there was no clinical or morphological follow-up for 15 patients (17 stents), i.e. 29.4% of patients were lost to follow-up.
Later follow-up thus concerned 35 patients (68.6%), i.e. 38 ARAIRs that were revascularized with success, with a time to monitoring of a mean of 12.4 months (3-64 months). The permeability rate of these 38 stents during the controls was 63.2%. For 28 stents (26 patients), the permeability control was systematic, after 6.7 months (3-12), with a permeability rate of 67.9%. For ten stents (nine patients), the time to control was longer: a mean of 29.8 months (18-64) with a permeability rate of 50%.
During these controls following in-stent revascularization, 14 stents (12 patients) had a second case of restenosis: 29.4% of 18 Genesis stents, 14.3% of seven Corinthian stents, 50% of six Palmaz stents, 100% for two Wallstents, 100% for two Ithmus stents, 100% for one Bluemax stent.
The difference in the restenosis rates of ostial and nonostial locations was significant (P = 0.049), but there was no difference depending on the other technical data (length of the stent, P = 0.18; diameter, P = 0.81), or the bilaterality or non bilaterality of the renal arterial damage.
Depending on the time interval between the initial stenting and the first ARAIR, the rates of second restenosis after revascularization were, respectively: 25% at 6 months, 38.5% at 1 year and 55.6% at more than 1 year.
The analysis of risk factors showed a rate of renewed instent restenosis that was significantly higher in patients who were smokers (86.7% versus 50%, P = 0.02) and in patients with obliterating lower limb arterial disease (52.9% versus 16.7%, P = 0.02).
There was no significant difference based on sex, age, weight, presence or absence of diabetes, hypertension or the type and number of antithrombotic medicinal products. When kidney function was impaired at the time of the initial stenting, the rate of second restenosis was significantly higher than when it was normal (47.4% versus 18.75%, P = 0.035).
After the first in-stent revascularization, data concerning blood pressure were only available in 34 out of 35 monitored patients (37 stents).
Concerning kidney function, data are only available in 30 patients (33 stents).
At the end of the monitoring period (a mean of 12.4 months with extreme values of 3 to 64 years), in 30 patients, there was in improvement in kidney function in 30% of patients, a stabilization in 50% of patients, and a deterioration in 20% of patients. There was a beneficial effect on blood pressure control in 52.9% of the 34 controlled patients. When kidney function was improved following the ARAIR treatment, the stent permeability rate was, after a mean of 12.7 months (3-64), 55.6% (five out of nine patients) and 73.3% (11 out of 15 patients) if plasma creatinine was stable. If there was kidney function deterioration, the permeability rate was 33.3% (two out of six patients). When blood pressure control was improved, there was a permeability rate after ARAIR treatment of 77.8% (14 out of 18), versus 50% (eight out of 16) when there was blood pressure control failure.
In 23 of the monitored patients, only one in-stent redilation was carried out.
All of the second restenoses diagnosed after a first in-stent dilation were treated. We therefore carried out several successive in-stent revascularization procedures in 12 patients (including two bilateral relapses and 14 stents) ( Table 2 ), due to relapsing in-stent obstructions following the first in-stent revascularization procedure.
During treatment of the second in-stent restenosis (12 patients, 14 stents), there was one case of technical failure (7.1%), but no complications. Nine redilations using a simple balloon (64.3%), one implantation of an additional stent (7.1%) and three dilations using cutting balloons (21.4%) were thus carried out with success. Seven stents (seven patients) were then controlled after a mean of 10.6 months (4-22), with a rate of third in-stent restenosis of 71.4%.
These ''third restenoses'' were treated with success with renewed dilation using a simple balloon (40%), a cutting balloon (40%) or a coated stent (one patient, 20%), with a permeability rate afterwards of 50% for two controlled stents: one occlusion after 4 months and one permeable stent after 10 months.
For these patients who had multiple revascularization procedures, clinically and regarding laboratory results after the second in-stent revascularization (12 patients, 14 stents), we noted a beneficial effect on kidney function in nine patients (75%: improvement in blood creatinine levels in four, stabilization in five), and an improvement in blood pressure control in three patients (25%). After the second in-stent revascularization, of the 11 patients treated with success, we had follow-up data concerning the kidney function of six patients. A beneficial effect was observed in five of them (83%) for nephrotic protection (two patients improved, three stable). For blood pressure monitoring, in five patients there was an improvement in blood pressure control for three of them (60%). Of the five patients treated for a third in-stent restenosis, there were three patients who were lost to follow-up. An improvement in the blood pressure values was observed for the two other patients, for whom kidney function was stable in one case, and deteriorated in the other.
Discussion
The weaknesses of this study are the low number of subjects, the high number of subjects who were lost to follow-up and the retrospective methodology, as well as the heterogeneity of the population, the model of stent initially used and the duration of follow-up. The revascularization technique of the restenoses was left to the appreciation of the operator, without randomization. In the analysis of the literature, we found comparable limits in the few series that have been published, particularly with low numbers of patients [11] [12] [13] [14] [15] [16] .
Certain authors [17] [18] [19] [20] have suggested a relationship between the ARAIR rate, female sex and diabetes. We did not find any impact due to these factors, but we observed a rate of second in-stent restenosis that was significantly higher in patients who were smokers (P = 0.02), with lower limb arterial disease (P = 0.02) or in case of RA in the ostial location (P = 0.049). Vignali et al. [12] found a relationship at the limit of significance (P = 0.03) between restenosis and a stent of less than 15 mm or more than 20 mm in length. A small diameter of the stented artery was for many authors a risk factor for restenosis, but with a variable threshold (4 or 5 mm) [12, 13, 17, 19, 21, 22] . Zeller et al. [16] , of 33 relapses of in-stent restenosis, found 69% of renewed restenoses after a second procedure (nine out of 13) for stents that were 5 mm in diameter, versus 33% for stents that were 6 mm in diameter (P = 0.09). In our series, the length and the diameter did not differ significantly to predict second restenosis. The comparison between the different platforms did not allow us to find a significant difference either (P = 0.058). To our knowledge, no significant difference has been demonstrated for the rate of first restenosis between the various models of stent [23] [24] [25] , without there being a comparative study.
The imaging method used to visualize the restenosis is not the object of a consensus: it can be Doppler sonography or an angiography scan, with the angiography MRI being handicapped by artefacts that prevent a reliable analysis of the in-stent lumen. The in-stent restenosis are most often diagnosed between the sixth and twelfth month following implantation, but it is not possible to know whether it is a significant period of peak in incidence due to the heterogeneity of the follow-up in the reported series. In-stent restenosis can occur with no clinical blood pressure or kidney function abnormalities. On the other hand, the blood pressure and kidney function values can deteriorate while the technical result remains stable. To our knowledge, there is no consensus on the monitoring calendar of these implanted stents. We carry out a control by angiography CT scan after 6 months to avoid false negatives too early on and to make it possible to treat in-stent restenosis as long as it is technically accessible, as the narrowing is often not completely critical at this point. If kidney function is deteriorated or concerning, a Doppler sonography is carried out as first-line imaging.
The treatment of ARAIR poses the question of the benefit/risk ratio of a new invasive procedure. Without a consensus, the decision is discussed on a case-by-case basis. If the initial indication has been established and if the benefit/risk ratio has not changed, the usefulness of the revascularization of a renal artery that has already been stented and restenosed is in agreement with the maintenance of the initially set objective: we would thus like to avoid the evolution towards complete occlusion and prolong any possible beneficial effects of the stenting on kidney function and blood pressure values. We have colligated the main results published for the treatment of the first ARAIR, respectively by use of a simple balloon (Table 3 ) and stent-in-stent (Table 4 ). The cutting balloon was used in this context by Otah et al. [29] and Munneke et al. [30] . To our knowledge, the use of DES to treat the first in-stent stenosis has not been reported. Brachytherapy has been the subject of the publication of isolated cases (Table 5 ) and a series of 13 patients, who found permeability at one year of 80%, with occlusion occurring at 18 months [26] . Table 6 makes it possible to compare the technical results at middle term of the treatment of a first ARAIR.
The morbidity and mortality rates remain limited (3.6% in our series). The rates of technical success are generally high (98.2% in our series). Different technical modalities have been used without standardization. Like Bax et al. [14] and Zeller et al. [16] , we first used redilation with a simple balloon, with a relapse rate at the end of the monitoring period of approximately 36%. The stent-in-stent was used when the redilation with a balloon was not satisfactory (relapse at middle term estimated to be 32%). Ndandu et al. [15] found a better stent permeability rate after a second stenting compared to angioplasty with a simple balloon: 29.4% versus 71.4% (10 out of 14) (P = 0.02). Under the same conditions of non-randomization, we found different data: 33.3% of restenosis (11 out of 33) after dilation with a simple balloon and 60% (three out of five) after renewed stenting. It is too early to come to a conclusion regarding the contribution of DES, which will surely be truly interesting when specific models for the renal artery become available.
We did not only use the balloon and the stent-in-stent for the treatment of the first in-stent restenosis: there is no large published series available proving the superiority of these methods, which are more difficult to implement and more costly, but which could be interesting for the treatment of patients at high risk of restenosis (particularly low diameter).
The clinical benefits obtained after treatment of a first ARAIR are comparable to those after primary angioplasty: benefits for the nephrotic capital in 80% of cases (improvement in kidney function in 30% and stabilization in 50%), beneficial effect on blood pressure control in 52.9% of cases, which pleads in favour of an interventional approach in case of a first ARAIR.
After the first ARAIR, the treatment of successive ARAIRs is not codified. Our results are disappointing from a morphological point of view, with a rate of third restenosis of 71.4% for seven controlled stents and 50% of fourth restenosis for two re-controlled stents (one out of two). The available results, which are limited, are not conclusive (Table 7) . Zeller et al. [16] found more renewed restenosis for stents measuring 5 mm in diameter (69%) than with stents measuring 6 mm in diameter (33%) (P = 0.09) after another intervention in 33 cases of relapsed in-stent restenosis. The only significant factor for renewed restenosis was the use of a cutting balloon (P < 0.001), with a rate evaluated at 100%, as opposed to 71% with a simple balloon, 43% after second stenting, 17% after implantation of a non active coated stent and 0% after use of an active coated stent. We only controlled one patient after treatment of repeated in-stent restenosis with a cutting balloon, which had relapsed. The results of the cutting balloon for the second and third instent restenoses appeared to be in the background in our review of the literature (80% of relapse, four out of five, with three relapses out of three in the series by Zeller et al. [16] . Zeller et al. consider that redilation with a balloon, a new bare stent, an active stent or a coated stent can provide favourable long-term permeabilities for the treatment of these repeated in-stent restenoses [16] . Surgical treatment could be discussed [41] . Certain authors currently consider that surgical treatment remains the best option when faced with restenosis, but it is still technically complex [42] . 
Conclusion
The endovascular treatment of ARAIR can be carried out with limited morbidity and mortality. The expected clinical benefits (blood pressure, preservation of the nephrotic capital) appear to be comparable to those of a first angioplasty. Screening must be systematic and early in order to facilitate therapy. For the treatment of first cases of restenosis, the efficacy of conventional techniques is imperfect, with permeability rates at 6 months that are limited. The other techniques (cutting balloon, brachytherapy) have not shown their superiority. The use of DES has been discussed for small-calibre arteries, but no specific equipment for the renal arteries is currently available. Therefore, we currently propose treating first restenosis with angioplasty via a simple balloon as first-line treatment, and possibly also with stenting depending on the residual lesions.
There is an even less clear hierarchy for the treatment of repeated restenoses. The results are not very compelling with a rate of third restenosis of 71% in our series, as opposed to 36% in the series by Zeller et al. [16] , where the cutting balloons have the least good results, while the use of surgery remains possible.
